Biopharmaceuticals in Medicare, Medicaid and Department of Veterans Affairs

PhRMA Statement on Rx Response’s Pharmacy Status Reporting Tool Activation in 11 States and the District of Columbia

Washington, D.C. (October 31, 2012)-- Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Matthew Bennett issued the following statement today on Rx Response activation in the wake of Hurricane Sandy:

PDUFA V Sets New Course for Regulatory Science – Joint BIO/PhRMA Statement

Washington, D.C. (October 1, 2012) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J. Castellani and Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood today released the following joint statement on the implementation of the Prescription Drug User Fee Act (PDUFA V):

PhRMA Statement Regarding Prescription Drug User Fee Act Reauthorization

Washington, D.C. (June 26, 2012) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J. Castellani issued the following statement today regarding reauthorization of the Prescription Drug User Fee Act (PDUFA):

“Today’s Senate passage of S. 3187, the Food and Drug Administration (FDA) Safety and Innovation Act of 2012, is the culmination of a multi-year effort on the part of biopharmaceutical companies, FDA, Congress, and stakeholders that featured unprecedented collaboration, public input, and bipartisanship.

New Study Details Foreign Efforts To Lure Biopharmaceutical Companies

Washington, D.C. (May 17, 2012) — Despite increasing budget pressures, countries around the world are making substantial investments in pro-innovation policies and programs to lure the biopharmaceutical research sector away from the U.S., finds a new study released by Battelle Technology Partnership Practice.

New Research Demonstrates Biopharmaceutical Sector’s Impact on U.S. Economy and Jobs

Washington, D.C. (July 11, 2011) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J. Castellani today issued the following statement on the biopharmaceutical research sector’s impact on jobs and the American economy:
 

Statement Regarding GAO Report on Drug Prices

Washington, D.C. (March 14, 2011) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J. Castellani issued the following statement regarding the Government Accountability Office’s (GAO) report on drug prices:

“We are pleased the GAO appropriately took into account the facts about how the biopharmaceutical marketplace works in its analysis of prescription medicine pricing trends. The report’s key finding shows prices have been increasing at a rate of 2.6% annually, which is lower than overall medical inflation.

Survey of Physicians About Pharmaceutical and Biotech Research Company Activities and Information

PhRMA Statement on the Independent Payment Advisory Board

Washington, D.C. (January 31, 2011) — Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Wes Metheny issued the following statement today:

“We continue to have significant concerns about the overly broad powers of the unelected IPAB, which could enact sweeping Medicare changes without Congress’ oversight and which would not be subject to judicial or administrative review.

“We believe IPAB will result in access problems for Medicare beneficiaries. Therefore, IPAB in its current form must be repealed.

Sino-Phirda and PhRMA Sign Joint Cooperation Agreement

Washington, D.C. (November 19, 2010) — Following a two day conference in Washington, DC, the China Pharmaceutical Industry Research and Development Association (SINO-PhIRDA) and the Pharmaceutical Research and Manufacturers of America (PhRMA) today signed a cooperation framework that embodies the intent of the multi-national pharmaceutical companies and Chinese pharmaceutical companies to continue a regular dialogue that will facilitate the two organizations working together.

Pages

Subscribe to RSS - Access